Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E1 and G1 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| E1 and G1 | DRUG | - |
Inclusion Criteria: * Informed consent obtained from participants * Clinical diagnosis Type 2 diabetes requiring treatment with Metformin and/or TZD and who are otherwise healthy * On a stable Metformin and/or TZD regimen for at least 60 days prior to screening * Maximum stimulated c-peptide level ...
E1 and G1 is an investigational small molecule combination being developed for Type 1 Diabetes and Type 2 Diabetes. It is currently in Phase 1 clinical development and is not approved by the FDA. The combination has been studied in patients with both types of diabetes in early-stage trials.
E1 and G1 is being developed by Opko Health Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol OPK. The company is conducting clinical trials to evaluate this combination therapy for the treatment of diabetes.
E1 and G1 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in Type 1 Diabetes and one in Type 2 Diabetes. The drug is investigational and has not been approved by regulatory authorities.
E1 and G1 has completed two Phase 1 clinical trials. NCT00239148 studied repeated doses of E1 in combination with G1 in 20 patients with Type 1 Diabetes. NCT00239187 studied the same combination in 30 patients with Type 2 Diabetes. Both trials were conducted in the United States.
E1 and G1 is a combination therapy that includes both E1 and G1 components. The clinical trials specifically evaluated the effects of E1 when given in combination with G1, rather than G1 alone. The development program focuses on this combined treatment approach for diabetes.